News | July 19, 2021
Lonza extends collaboration with Biopharma company
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The first batch will be shipped to the Gamaleya Center for the quality control
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Financial support is being provided as a grant from the Government of India
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
